Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection

Basit Öğe Kaydı
dc.contributor.authorAltıntepe, Lütfullah
dc.contributor.authorKurtoğlu, E
dc.contributor.authorTonbul, Halil Zeki
dc.contributor.authorYeksan, M
dc.contributor.authorYildiz, A
dc.contributor.authorTurk, S
dc.date.accessioned2020-03-26T16:55:20Z
dc.date.available2020-03-26T16:55:20Z
dc.date.issued2004
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Chronic hepatitis C virus (HCV) infection is a common infectious agent in chronic hemodialysis (HD) patients. In this prospective case-control study, we aimed to investigate the influence of chronic HCV infection on erythropoietin (EPO) and iron requirement in HD patients. Patients and methods: 49 HD patients (24 male, 25 female, mean age 47 +/- 15 years) were included. The mean time spent on dialysis was 39 +/- 38 months, and follow-up time was 1 year for this study. Biochemical analyses and complete blood counts together with iron status of the patients (transferrin saturation and serum ferritin levels) were measured monthly. Highly sensitive C-reactive protein (hs-CRP) levels were measured within 3-month intervals. Endogenous EPO levels were measured by enzyme-linked immunoassay 2 weeks after cessation of EPO treatment. Results: Eleven of the HD patients (22%) were anti-HCV(+). There was no difference in age, sex, time on dialysis, distribution of primary renal diseases, predialytic BUN, Kt/V, albumin and i-PTH levels between HCV(+) and (-) patients. Anti-HCV-positive patients required significantly lower weekly doses of EPO (87 +/- 25 IU/kg vs 129 +/- 11 IU/kg, p = 0.042) and iron (16.8 +/- 12.2 mg vs 32.6 +/- 16.1 mg, p = 0.02) replacement than anti-HCV(-) group; hs-CRP levels were similar between study groups. Serum endogenous EPO levels were significantly higher in HCV(+) patients than HCV(-) HD patients (9.43 +/- 6.47 mU/ml vs 3.59 +/- 2.08 mU/ml, p = 0.008). Conclusion: Anti-HCV(+) HD patients had higher serum EPO levels and required less EPO and iron replacement as compared to anti-HCV(-) patients. Because of the changes in iron metabolism, iron treatment should be carefully administered in HD patients with HCV.en_US
dc.identifier.endpage351en_US
dc.identifier.issn0301-0430en_US
dc.identifier.issue5en_US
dc.identifier.pmid15182130en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage347en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/19117
dc.identifier.volume61en_US
dc.identifier.wosWOS:000221169400007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDUSTRI-VERLAG DR KARL FEISTLEen_US
dc.relation.ispartofCLINICAL NEPHROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjecterythropoietinen_US
dc.subjecthepatitis Cen_US
dc.subjecthemodialysisen_US
dc.subjectironen_US
dc.titleLower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infectionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Lowererythropoietinandironsupplementation.pdf
Boyut:
185.78 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu